Beckley Psytech, a company addressing neurological and psychiatric disorders through the application of psychedelic medicines, announced that the first healthy volunteers have been dosed in a Phase I clinical trial exploring the safety and pharmacokinetics of BPL-003, Beckley Psytech’s second formulation of 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT). The study… Read More
News round-up by DDW’s Megan Thomas for 4-8 April When considering trends in the drug discovery industry, the use of technology to advance treatments and therapeutics is consistently observed. DDW rounds up five of this week’s top news stories which reveal this theme of technology, AI and… Read More
At the end of last month, DDW’s Megan Thomas attended ELRIG’s Research & Innovation 2022: Innovations for Tomorrow’s Drug Discovery, at The King’s Centre in Oxford, UK. The four sessions addressed aspects of innovation across drug discovery and placed an emphasis on both the digital age and novel modalities: Omics… Read More
As we celebrate World Health Day, Lu Rahman looks at some of the key drug discovery and development successes over the last year that have significantly helped improved the health and wellbeing of the global population. Malaria breakthroughs According to The World Health Organization (WHO) more than a million people in Africa… Read More
New global data analysis from Phesi shows the extent of the impact from the war in Ukraine on clinical development. Phesi analysed pivotal trials sponsored by pharmaceutical companies that represent the most critical global clinical development activities. The findings The findings show that… Read More
Cyxone, a Swedish clinical stage biotech company developing disease modifying therapies for diseases such as rheumatoid arthritis (RA), confirms the previously demonstrated favourable safety and tolerability profile for its drug candidate Rabeximod, in the Clinical Study Report from its exploratory Phase II study in Covid-19 patients. Other… Read More
In this whitepaper, we will expand on key factors – cost, time, and innovation – and illustrate how integrating these factors will minimise the challenges and ensure success in outsourcing drug discovery. Learn about: Opportunities, options, and outsourcing of drug discovery programs Hidden costs vs. hidden value Impact on… Read More
In this whitepaper, we will expand on key factors – cost, time, and innovation – and illustrate how integrating these factors will minimise the challenges and ensure success in outsourcing drug discovery. Learn about: Opportunities, options, and outsourcing of drug discovery programs Hidden costs vs. hidden value Impact on timelines… Read More
Medical technology company BD has recently released the BD Rhapsody TCR/BCR Multiomic Assay, a set of reagents that enables researchers to more easily and comprehensively analyse cells, providing a tool to advance research in autoimmune disorders, immuno-oncology and infectious diseases. The multiomic assay supplies immunology researchers the… Read More
New results from an observational data analysis of asthma inhaler therapy found that short-acting beta2-agonist (SABA) reliever overuse is a global issue adversely impacting asthma outcomes.1,2 Data from across the SABA Use IN Asthma (SABINA) global programme have been published in The Journal of Allergy… Read More
According to the Medicines for Malaria Venture (MMV),the Australian Therapeutic Goods Administration (TGA) has approved the use of single-dose Kozenis (tafenoquine) in children aged two years and above in combination with chloroquine for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria. The approval… Read More
This is the latest episode of the free DDW podcast, “What does gene-based medicine have to offer?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW. The articles are called “Lipidomics in biomedical research: chance and challenges” and “Exploring gene-based medicine’s true potential”. Read More
This is the latest episode of the free narrated DDW podcast, “What does gene-based medicine have to offer?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW. The articles are called “Lipidomics in biomedical research: chance and… Read More
News round-up by DDW’s Megan Thomas for 28 March – 1 April, 2022 From Covid updates to life-saving investments, this week’s news shows how valuable the drug discovery industry is and the impact it makes. 1. Covid-19 approval milestone for those who can’t be… Read More
This decade is the age of the biobank, says Lauren Taylor, a scientist and solutions manager in Digital Sciences at Thermo Fisher Scientific. She shares her thoughts on the importance of IoT and LIMS with DDW. Never have we seen such investment, growth and interest in the meticulous collection of… Read More
Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and… Read More
